Search results
Results From The WOW.Com Content Network
A coalition of attorneys general from nearly every state filed a massive lawsuit Wednesday charging 26 generic drug companies and 10 executives of conspiring to reduce competition and raise prices ...
(Reuters) -A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies ...
Medicare fraud, kickbacks Zocor, Vioxx, Pepsid: False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma [15] $601 million Off-label promotion Oxycontin: False Claims Act 2010 Allergan [16] $600 million Off-label promotion Botox: False Claims Act, FDCA 2010 AstraZeneca [17] $520 million Off-label promotion, kickbacks Seroquel: False Claims ...
Fake news websites played a large part in the online news community during the election, reinforced by extreme exposure on Facebook and Google. [35] Approximately 115 pro-Trump fake stories were shared on Facebook a total of 30 million times, and 41 pro-Clinton fake stories shared a total of 7.6 million times.
Michigan consumers are getting hit hard by fraud: Michigan consumers reported losing $151.7 million in 2023 to all types of fraud and scams, according to the Consumer Sentinel Network Data Book ...
Massachusetts v. Purdue is a lawsuit filed on August 14, 2018, suing the Stamford, Connecticut-based company Purdue Pharma LP, which created and manufactures OxyContin, "one of the most widely used and prescribed opioid drugs on the market", and Purdue's owners, the Sacklers [1] accusing them of "widespread fraud and deception in the marketing of opioids, and contributing to the opioid crisis ...
Several headwinds are impacting the company, including generic competition for its blockbuster drug Stelara, the ongoing talc lawsuit (which could see a final decision in the first half of the ...
United States of America v. Regenerative Sciences, LLC, 741 F.3d 1314 (D.C. Cir. 2014), [1] was a decision in the United States Court of Appeals for the District of Columbia Circuit filed on February 4, 2014 concerning more than minimally manipulated cell therapies and whether they are considered part of medical practice or a drug, the latter subjecting it to regulation under the Food and Drug ...